dr. karmali on novel agents in relapsed/refractory mcl
Published 5 years ago • 49 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:05
dr. goy on combinations with novel agents in relapsed/refractory mcl
-
1:31
dr. karmali on challenges in mcl
-
0:50
dr. karmali on treating older patients with mcl in the rituximab era
-
1:21
dr. karmali on optimizing maintenance therapy in older patients with mcl
-
1:16
dr. karmali on the importance of evaluating older patients with mcl in the rituximab era
-
0:59
dr. karmali on limitations of intensive therapy in older/medically unfit patients with mcl
-
3:51
selecting therapy for relapsed/refractory mcl
-
1:20
dr. goy the evolution of treatment in relapsed/refractory mcl
-
3:23
novel car-t cell therapy shows promise against calreticulin mutant neoplasms
-
12:51
lori parisi, janssen oncology, discusses a treatment for mantle cell lymphoma
-
1:01:35
follicular & mantle cell lymphoma with professor simon rule
-
1:28
dr. karmali on the toxicity profile of ibrutinib maintenance in mcl
-
1:11
dr. karmali on next steps of research regarding ibrutinib maintenance in mcl
-
2:07
dr. wang discusses the treatment of relapsed/refractory mcl
-
1:25
dr. lee on early efficacy data with cirmtuzumab/ibrutinib in relapsed/refractory mcl
-
2:20
dr. karmali on ibrutinib maintenance following induction in untreated mcl
-
1:08
dr. song on zanubrutinib activity in relapsed/refractory mcl
-
1:11
dr. andreadis on car t-cell therapy in relapsed/refractory mcl
-
1:36
dr. rule on long-term follow-up of ibrutinib monotherapy in relapsed/refractory mcl
-
19:58
new agents for mantle cell lymphoma
-
4:06
identifying unmet needs in relapsed/refractory mcl
-
1:04
dr. wang on the safety profile of brexucabtagene autoleucel in relapsed/refractory mcl